MSC Immune Modulation for Canine Atopic Dermatitis Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for canine atopic dermatitis lack reliable biomarkers, and existing treatments are ineffective in addressing the immune imbalance underlying the condition.
Innovation Solution
Utilize specific marker expression levels, such as miR-203, miR-483, PIAS1, RORA, SH2B1, and PDE4D, to diagnose atopic dermatitis and administer mesenchymal stem cells (MSCs) to modulate the immune response, which are modified or stimulated to produce cytokines for treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If clinical examination and exclusion methods are used for diagnosis, then the diagnostic process is simple and accessible, but the reliability and accuracy of diagnosis is insufficient due to lack of reliable biomarkers
Solution Approach 1:
The patent replaces the traditional clinical examination approach with molecular biomarker detection. By detecting specific miRNA expressions (miR-203, miR-483) and gene expressions (PIAS1, RORA, SH2B1, PDE4D) in peripheral blood samples, the diagnosis transitions from subjective clinical assessment to objective molecular measurement, significantly improving diagnostic reliability while maintaining simplicity through standardized laboratory testing protocols
2Reliability
If conventional treatments are used for atopic dermatitis, then the treatment approach is straightforward, but the effectiveness is insufficient due to inability to address underlying immune imbalance
Solution Approach 1:
The patent applies parameter changes by modifying mesenchymal stem cells through specific treatment protocols to alter their immunomodulatory properties. The MSCs are treated with cytokines (IL-4, IL-13, IL-31) and other factors to enhance their ability to restore immune balance in atopic dermatitis patients, transforming conventional MSC therapy into a targeted treatment that addresses the underlying pathophysiology
Solution Approach 2:
The patent uses mesenchymal stem cells as an intermediary substance to mediate the treatment effect. The MSCs serve as a carrier that delivers immunomodulatory cytokines and facilitates immune rebalancing between Th1 and Th2 responses, acting as a biological mediator that restores homeostasis in the immune system without requiring direct intervention with the immune cells themselves
Data Source
AI summary
Provided are methods of diagnosis and treatment of atopic dermatitis.